{"filing":{"accession_number":"0001654954-26-008347","cik":"0001304161","ticker":"PBSV","company_name":"Pharma-Bio Serv, Inc.","form":"8-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"pbsv_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1304161/000165495426008347/pbsv_8k.htm"},"events":[{"id":33379,"run_id":30689,"accession_number":"0001654954-26-008347","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The filing discloses quarterly and nine-month financial results for the period ended July 31, 2026, including revenues of $2.3 million and $7.3 million respectively, and net income of $252 thousand for the nine-month period. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes comparative performance metrics and management commentary on financial improvements.","company_name":"Pharma-Bio Serv, Inc.","ticker":"PBSV","filing_date":"2026-09-14","form":"8-K","submitted_at":null,"items":[{"id":36824,"accession_number":"0001654954-26-008347","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses quarterly and nine-month financial results for the period ended July 31, 2026, including revenues of $2.3 million and $7.3 million respectively, and net income of $252 thousand for the nine-month period. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes comparative performance metrics and management commentary on financial improvements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T21:23:47.435567+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36824,"accession_number":"0001654954-26-008347","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses quarterly and nine-month financial results for the period ended July 31, 2026, including revenues of $2.3 million and $7.3 million respectively, and net income of $252 thousand for the nine-month period. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes comparative performance metrics and management commentary on financial improvements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T21:23:47.435567+00:00","company_name":"Pharma-Bio Serv, Inc.","ticker":"PBSV","filing_date":"2026-09-14"}]}